Skip to content

Viktoria Friedrich's lobbying: the registrations they file and every meeting they've reported since November 2021.

← Lobbying

Registrant (responsible officer)

Viktoria Friedrich

Country President and General Manager - Pharmaceutical Division

For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.

Meetings this Parliament
17
Since Nov 2021
21
Active registrations
1

Registered for

Reported meetings

  • Bayer Inc.
    • Julie Harb · Senior Policy Advisor, Prime Minister's Office (PMO)
    Advocacy as it relates to the US Administration’s Most Favored Nation drug pricing policy and its potential impact for Canada Read more

    Domestic and international trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.

    Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.

    Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians.

    Official report

  • Bayer Inc.
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    Domestic and international trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines. Read more

    Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.

    Official report

  • Bayer Inc.
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy. Read more

    Advocacy as it relates to the US Administration’s Most Favored Nation drug pricing policy and its potential impact for Canada

    Domestic and international trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.

    Official report

  • Bayer Inc.
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians. Read more

    Advocacy as it relates to the US Administration’s Most Favored Nation drug pricing policy and its potential impact for Canada

    Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.

    Official report

  • Bayer Inc.
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians. Read more

    Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.

    Advocacy as it relates to the US Administration’s Most Favored Nation drug pricing policy and its potential impact for Canada

    Official report

  • Bayer Inc.
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy. Read more

    Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians.

    Official report

  • Bayer Inc.
    • Simone Racanelli · Senior Advisor, Stakeholder Relations, Innovation, Science and Economic Development Canada (ISED)
    Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians. Read more

    Advocacy as it relates to the US Administration’s Most Favored Nation drug pricing policy and its potential impact for Canada

    Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.

    Official report

  • Bayer Inc.
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • David McFarlane · Director of Policy, Innovation, Science and Economic Development Canada (ISED)
    Advocacy as it relates to the US Administration’s Most Favored Nation drug pricing policy and its potential impact for Canada Read more

    Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.

    Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians.

    Official report

  • Bayer Inc.
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy. Read more

    Domestic and international trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.

    Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians.

    Official report

  • Bayer Inc.
    • Danièle Henkel · Senator, Senate of Canada

    S-243

    Communicating with government officials on Bill S-243, An Act to establish a national framework for women’s health in Canada. Providing guidance, subject matter expertise and relevant information to help inform future policy development. Read more

    Official report

  • Bayer Inc.
    • Manuela Tomic · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to- reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Official report

  • Bayer Inc.
    • Miro Froehlich · Director of Policy, Privy Council Office (PCO)
    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to- reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Official report

  • Bayer Inc.
    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to- reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Official report

  • Bayer Inc.
    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to- reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Official report

  • Bayer Inc.
    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to- reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Official report

  • Bayer Inc.
    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to- reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Official report

  • Bayer Inc.
    • Noemie Fiset-Tremblay · Chief of Staff to the Minister, Employment and Social Development Canada (ESDC)
    Canadian Labour Code: Occupational Health and Safety. Elevating awareness of treatment and therapeutic availability.

    Official report

  • Bayer Inc.
    International trade policy and free trade agreements with respect to the biopharmaceutical industry

    Official report

  • Bayer Inc.
    • Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    International trade policy and free trade agreements with respect to the biopharmaceutical industry

    Official report

  • Bayer Inc.
    • Tom Kmiec · Member of Parliament
    • Blaine Calkins · Member of Parliament
    • Stephen Ellis · Member of Parliament, House of Commons
    • Earl Dreeshan · Member of Parliament, House of Commons

    HealthIntellectual PropertyScience and Technology

    Official report

  • Bayer Inc.
    • Eshan Naik · Director of Policy, Health Canada (HC)

    HealthScience and Technology

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.